Neurosense Therapeutics News - October 5, 2026
NeuroSense Fights to Stay on Nasdaq — But Can a Small Biotech Buy Enough Time to Survive?
Shares of NeuroSense Therapeutics surged 15.4% to $4.54 on October 5, snapping a five-session slide, after the company disclosed plans to appeal Nasdaq's move...
🟢 Neurosense Therapeutics is trading 15.4% up today amid plan to appeal Nasdaq compliance determination
Neurosense Therapeutics is trading 15.4% higher at $4.54; its October 2 plan to appeal Nasdaq’s minimum market-value determination is the clearest relevant...
🟢 Neurosense Therapeutics is trading 6.23% up today amid planned appeal of Nasdaq delisting determination
Neurosense Therapeutics is trading at $4.18, up 6.23% on October 5; no catalyst was identified. - On October 2, the company said it had failed Nasdaq’s $35...